Cargando…

High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children

Pulmonary complications are an important cause for treatment-related morbidity and mortality in hematopoietic cell transplantation (HCT) in children. The aim of this study was to investigate the yield of our pre-HCT pulmonary screening program. We also describe our management guidelines based on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Versluys, Anne Birgitta, van der Ent, Korstiaan, Boelens, Jaap J., Wolfs, Tom, de Jong, Pim, Bierings, Marc B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128354/
https://www.ncbi.nlm.nih.gov/pubmed/26071867
http://dx.doi.org/10.1016/j.bbmt.2015.06.002
_version_ 1783516546697527296
author Versluys, Anne Birgitta
van der Ent, Korstiaan
Boelens, Jaap J.
Wolfs, Tom
de Jong, Pim
Bierings, Marc B.
author_facet Versluys, Anne Birgitta
van der Ent, Korstiaan
Boelens, Jaap J.
Wolfs, Tom
de Jong, Pim
Bierings, Marc B.
author_sort Versluys, Anne Birgitta
collection PubMed
description Pulmonary complications are an important cause for treatment-related morbidity and mortality in hematopoietic cell transplantation (HCT) in children. The aim of this study was to investigate the yield of our pre-HCT pulmonary screening program. We also describe our management guidelines based on these findings and correlate them with symptomatic lung injury after HCT. Since 2008, all patients undergo a dedicated pulmonary screening consisting of pulmonary function test (PFT), chest high-resolution computed tomography (HRCT), and bronchial alveolar lavage (BAL) before HCT. We systematically evaluated the yield during the first 5 years of our screening program. We included 142 consecutive children. In 74% of patients, abnormalities were found. In 66% of patients, 1 or more PFT results were <80% of normal. Chest HRCT showed abnormalities in 55%; 19% of these abnormalities were considered “clinically significant.” BAL was abnormal in 43% of patients; respiratory viruses (PCR) were found in 35 patients, fungi (antigen or culture) in 21, and bacteria (culture) in 22. All 3 screening tests contributed separately to clinically relevant information regarding pulmonary status in these pre-HCT children. In 46 patients (33%), screening results had diagnostic and/or therapeutic implications. We found an association between pre-SCT HRCT findings and lung injury after transplantation. Pre-HCT screening with the combination of 3 modalities, reflecting different domains of respiratory status (function, structure, and microbial colonization), reveals important abnormalities in a substantial number of patients. Whether this improves patient outcome requires further investigation.
format Online
Article
Text
id pubmed-7128354
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71283542020-04-06 High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children Versluys, Anne Birgitta van der Ent, Korstiaan Boelens, Jaap J. Wolfs, Tom de Jong, Pim Bierings, Marc B. Biol Blood Marrow Transplant Clinical Research: Pediatric Pulmonary complications are an important cause for treatment-related morbidity and mortality in hematopoietic cell transplantation (HCT) in children. The aim of this study was to investigate the yield of our pre-HCT pulmonary screening program. We also describe our management guidelines based on these findings and correlate them with symptomatic lung injury after HCT. Since 2008, all patients undergo a dedicated pulmonary screening consisting of pulmonary function test (PFT), chest high-resolution computed tomography (HRCT), and bronchial alveolar lavage (BAL) before HCT. We systematically evaluated the yield during the first 5 years of our screening program. We included 142 consecutive children. In 74% of patients, abnormalities were found. In 66% of patients, 1 or more PFT results were <80% of normal. Chest HRCT showed abnormalities in 55%; 19% of these abnormalities were considered “clinically significant.” BAL was abnormal in 43% of patients; respiratory viruses (PCR) were found in 35 patients, fungi (antigen or culture) in 21, and bacteria (culture) in 22. All 3 screening tests contributed separately to clinically relevant information regarding pulmonary status in these pre-HCT children. In 46 patients (33%), screening results had diagnostic and/or therapeutic implications. We found an association between pre-SCT HRCT findings and lung injury after transplantation. Pre-HCT screening with the combination of 3 modalities, reflecting different domains of respiratory status (function, structure, and microbial colonization), reveals important abnormalities in a substantial number of patients. Whether this improves patient outcome requires further investigation. American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. 2015-09 2015-06-11 /pmc/articles/PMC7128354/ /pubmed/26071867 http://dx.doi.org/10.1016/j.bbmt.2015.06.002 Text en Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical Research: Pediatric
Versluys, Anne Birgitta
van der Ent, Korstiaan
Boelens, Jaap J.
Wolfs, Tom
de Jong, Pim
Bierings, Marc B.
High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children
title High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children
title_full High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children
title_fullStr High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children
title_full_unstemmed High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children
title_short High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children
title_sort high diagnostic yield of dedicated pulmonary screening before hematopoietic cell transplantation in children
topic Clinical Research: Pediatric
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128354/
https://www.ncbi.nlm.nih.gov/pubmed/26071867
http://dx.doi.org/10.1016/j.bbmt.2015.06.002
work_keys_str_mv AT versluysannebirgitta highdiagnosticyieldofdedicatedpulmonaryscreeningbeforehematopoieticcelltransplantationinchildren
AT vanderentkorstiaan highdiagnosticyieldofdedicatedpulmonaryscreeningbeforehematopoieticcelltransplantationinchildren
AT boelensjaapj highdiagnosticyieldofdedicatedpulmonaryscreeningbeforehematopoieticcelltransplantationinchildren
AT wolfstom highdiagnosticyieldofdedicatedpulmonaryscreeningbeforehematopoieticcelltransplantationinchildren
AT dejongpim highdiagnosticyieldofdedicatedpulmonaryscreeningbeforehematopoieticcelltransplantationinchildren
AT bieringsmarcb highdiagnosticyieldofdedicatedpulmonaryscreeningbeforehematopoieticcelltransplantationinchildren